Entrada Therapeutics, Inc. (TRDA) company profile
Close on Nov 13, 2026Market cap $198.19MP/E –Yield –
About Entrada Therapeutics
Pharmaceutical Preparations, SIC 2834
Entrada Therapeutics is a clinical-stage biopharmaceutical company focused on developing a class of genetic medicines that target disease-causing mechanisms inside cells. Utilizing its proprietary Endosomal Escape Vehicle platform, the company creates intracellular therapeutics by conjugating small cyclic peptides with oligonucleotides or proteins. Its core development pipeline focuses on rare neuromuscular conditions, particularly Duchenne muscular dystrophy, through exon-skipping candidates such as ENTR-601-44, ENTR-601-45, ENTR-601-50, and ENTR-601-51. In addition, the company collaborates with Vertex Pharmaceuticals to advance VX-670 for myotonic dystrophy type 1 and pursues preclinical programs for inherited ocular diseases, including ENTR-801 for Usher syndrome type 2A.
The company conducts clinical trials across multiple regions, with active development activities and regulatory engagements in the United States, the United Kingdom, and the European Union. Its pipeline targets rare genetic disease populations, addressing thousands of eligible patients amenable to exon-skipping therapies in both the United States and Europe. The provided text does not state the location of the company's headquarters.
Summary of the business section of Entrada Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Entrada Therapeutics, Inc.
- Headquarters
- Boston, MA
- Address
- One Design Center Place, Suite 17-500 02210
- Phone
- (857) 305-1825
- Website
- entradatx.com
- Employees
- 152, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- TRDA
- Exchange
- Nasdaq
- IPO date
- Nov 1, 2021
- Shares outstanding
- 39M, Jul 31, 2026
- Public float
- $191.20M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1689375
- CUSIP
- 29384C108
- ISIN
- US29384C1080
- FIGI
- BBG00MTSMC16
- Share class FIGI
- BBG00MTSMC25
- EIN
- 81-3983399
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Dipal Doshi | CEO, Director | 517,290 |
| Kory James Wentworth | Chief Financial Officer | 117,277 |
| Natarajan Sethuraman | President, Research & Develop. | 214,238 |
| Nathan J. Dowden | President & COO | 196,060 |
| Kush Parmar | Director | 3,784,650 |
| Maha Radhakrishnan | Director | – |
| Peter S. Kim | Director | 117,412 |
| Mary Thistle | Director | – |
| Bernhardt G. Zeiher | Director | 5,000 |
| Gina Chapman | Director | – |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Dipal Doshi Chief Executive Officer | $635.00K | $1.39M | $1.45M | $349.25K | $14.00K | $3.84M | -1% |
| Natarajan Sethuraman Ph. D. President of Research and Development | $520.00K | $725.95K | $760.36K | $234.00K | $14.00K | $2.25M | +15% |
| Nathan J. Dowden President and Chief Operating Officer | $499.20K | $725.95K | $760.36K | $224.64K | $13.34K | $2.22M | -10% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Nov 1, 2021
- Offer price
- $20.00
- Securities offered
- 9,075,000
- Gross proceeds
- $181.50M
- Exchange
- Nasdaq
- First trading day
- Oct 29, 2021
- First-day close
- $23.95+19.8%
- Lock-up ends (est.)
- Apr 27, 2022
“The initial public offering price per share is $20.00.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of February 19, 2026, we had 152 full-time employees, including a total of 64 employees with doctoral degrees or above.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 1, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 26, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
| Nov 10, 2016 | Name change | Name changed from CycloPorters, Inc. to Entrada Therapeutics, Inc. |
See a number that looks wrong?